Revenue (Quarterly) Chart

View Revenue (Quarterly) for VYCO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue (Quarterly) Chart
Start Trial

Historical Revenue (Quarterly) Data

View and export this data back to 2009. Start Trial.
Date Value
June 30, 2026 0.4183M
March 31, 2026 0.4585M
December 31, 2025 0.4169M
September 30, 2025 0.5138M
June 30, 2025 0.4964M
March 31, 2025 0.4364M
December 31, 2024 0.4552M
September 30, 2024 0.3909M
June 30, 2024 0.4063M
March 31, 2024 0.337M
December 31, 2023 0.3082M
September 30, 2023 0.3086M
June 30, 2023 0.4828M
March 31, 2023 0.361M
December 31, 2022 0.2713M
September 30, 2022 0.31M
June 30, 2022 0.3279M
March 31, 2022 0.3138M
December 31, 2021 0.2737M
September 30, 2021 0.3321M
June 30, 2021 0.4914M
March 31, 2021 0.2957M
December 31, 2020 0.2916M
September 30, 2020 0.2759M
June 30, 2020 0.2443M
Date Value
March 31, 2020 0.3302M
December 31, 2019 0.3315M
September 30, 2019 0.3229M
June 30, 2019 0.4119M
March 31, 2019 0.3507M
December 31, 2018 0.4264M
September 30, 2018 0.4562M
June 30, 2018 0.3017M
March 31, 2018 0.3251M
December 31, 2017 0.2698M
September 30, 2017 0.3791M
June 30, 2017 0.3077M
March 31, 2017 0.4284M
December 31, 2016 0.3474M
September 30, 2016 0.3258M
June 30, 2016 0.3794M
March 31, 2016 0.4001M
December 31, 2015 0.2812M
September 30, 2015 0.2429M
June 30, 2015 0.286M
March 31, 2015 0.3286M
December 31, 2014 0.2593M
September 30, 2014 0.3343M
June 30, 2014 0.2985M
March 31, 2014 0.3581M

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (Quarterly) Range, Past 5 Years

View Revenue (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (Quarterly) Benchmarks

View Revenue (Quarterly) Benchmarks
Start Trial
Abbott Laboratories 12.59B
AngioDynamics, Inc. 86.61M
Alphatec Holdings, Inc. 213.51M
AtriCure, Inc. 153.60M
Baxter International, Inc. 2.96B